Finally, a recent study showed that HER3 is used to couple EGFR to the PI3K/Akt pathway in gefitinib-sensitive NSCLC cell lines harboring wild-type and mutant EGFR (Engelman et al, 2005). Here, ERBB3 is linked to non-small cell lung carcinoma.